This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-preview: Archive
Globus Medical (GMED) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
GMEDPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Exploring Analyst Estimates for JFrog (FROG) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for JFrog (FROG), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
FROGNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Somnigroup International (SGI) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Somnigroup International (SGI) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
SGINegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Exploring Analyst Estimates for American Healthcare REIT (AHR) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of American Healthcare REIT (AHR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
AHRPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Seeking Clues to News Corp. (NWSA) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for News Corp. (NWSA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
NWSANegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Texas Roadhouse (TXRH) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Texas Roadhouse (TXRH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
TXRHNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Gear Up for DuPont de Nemours (DD) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of DuPont de Nemours (DD) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
DDNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Exploring Analyst Estimates for Yelp (YELP) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Yelp (YELP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
YELPNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Gear Up for M/A-Com (MTSI) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for M/A-Com (MTSI), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
MTSIPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Unlocking Q3 Potential of Main Street Capital (MAIN): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Main Street Capital (MAIN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
MAINNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Unlocking Q3 Potential of Paramount Skydance (PSKY): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Paramount Skydance (PSKY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
PSKYPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Unveiling Solventum (SOLV) Q3 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Solventum (SOLV) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
SOLVPositive Net Change
earnings earnings-estimates earnings-expectations earnings-preview
Insights Into Shift4 Payments (FOUR) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Shift4 Payments (FOUR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
FOURNegative Net Change
earnings earnings-estimates earnings-expectations earnings-preview
CELH to Report Q3 Earnings: Buy, Sell or Hold the Stock Now?
by Vrishali Bagree
CELH's Q3 momentum builds on brand strength, Alani Nu integration and expanding reach amid rising wellness trends.
KOPositive Net Change PEPPositive Net Change MNSTPositive Net Change CELHNegative Net Change
consumer-staples earnings-preview food
Arm Holdings Stock Before Q2 Earnings: To Buy or Not to Buy?
by Shuvra Shankar Dey
ARM's Q2 results are expected to show strong royalty and licensing gains, but after a 38% rally, investors may want to wait for a better entry point.
QCOMNegative Net Change AAPLNegative Net Change ARMNegative Net Change
computers earnings-preview electronics semiconductor tech-stocks
Should You Buy, Hold or Sell Affirm Stock Before Q1 Earnings Report?
by Kaibalya Pravo Dey
AFRM heads into its Q1 FY2026 report with strong revenue and earnings growth estimates, but its premium valuation will likely test investor patience.
VNegative Net Change PYPLNegative Net Change AFRMNegative Net Change
earnings-outlook earnings-preview fin-tech finance payments
Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VRDNPositive Net Change IVVDPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Plug Power (PLUG) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Plug Power (PLUG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLUGNegative Net Change ROKNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Sky Harbour Group Corporation (SKYH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Sky Harbour Group (SKYH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKYHNegative Net Change RKLBPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
SKYX Platforms Corp. (SKYX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
SKYX PLATFORMS (SKYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKYXPositive Net Change BTDRNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OBIONegative Net Change ZYMEPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ondas Holdings Inc. (ONDS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ondas (ONDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ONDSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OVIDPositive Net Change RNANegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOLTNegative Net Change PTGXPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FATENegative Net Change ARCTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate